SecBot SecBot
SC 13G ·Filed Nov 10, 2026

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonimmediate Processed6d 19h ago SEC0000093751-26-000677
Passive investor 5%+ stake
Actionable Insight • Neutral

This filing confirms State Street's continued passive ownership at a stable level. No change in investment thesis; monitor for any future 13D conversion or material stake changes.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$8.08
T+0 close · Nov 10, 2026 · via day close
Latest settled
+0.12%
T+1 · $8.09
Vs SPY
−1.20%
α at T+1
Next horizon
T+5
in 3h
  1. T+0 · Nov 10 $8.08entry
  2. T+1 · 6d ago +0.12%α −1.20% · $8.09
  3. T+4 · todayOpen
  4. T+5 · in 3h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

State Street Corp disclosed a 4.8% passive stake in Iovance Biotherapeutics as of September 30, 2026, via a Schedule 13G filing. This is a routine update of its existing passive position, consistent with prior filings, and follows the company's strong Q3 earnings report.

Key Financial Metrics

Stake
4.8%
Investor
STATE STREET CORP

Key Facts

  • State Street Corp reported beneficial ownership of 21,695,003 shares of Iovance common stock as of September 30, 2026.
  • The stake represents 4.8% of shares outstanding.
  • The filing is a Schedule 13G, certifying passive investment intent with no control or influence purpose.
  • State Street has filed multiple prior 13Gs for Iovance, indicating a continuing passive position.

Financial Impact

State Street's stake of 21,695,003 shares is valued at approximately $3.7B market cap * 4.8% = ~$177.6M based on the market data snapshot.

ownership

Risk Factors

  • No activist intent indicated; passive filing limits immediate market impact.
  • Stake is below 5% threshold for mandatory disclosure, suggesting no imminent material change.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000093751-26-000677
Document: 0000093751-26-000677-index.html0000093751-26-000677
Document: 0000093751-26-000677.txt0000093751-26-000677

Track record

21 reports on IOVA

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $8.08 Now $7.55 −6.56% settles Dec 9
  2. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $8.04 Now $7.55 −6.09% settles Dec 7
  3. Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
  4. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
  5. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
  6. Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
  7. Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
  8. Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
  9. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
  10. Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 5h 54m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026